Following on from information provided to NICE by the company, the appraisal of Melanoma (advanced and metastatic) - temozolomide was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
 
Status Discontinued
Decision Selected
Process TA

Timeline

Key events during the development of the guidance:

Date Update
16 November 2022 Discontinued. Following on from information provided to NICE by the company, the appraisal of Melanoma (advanced and metastatic) - temozolomide was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
19 January 2018 In progress. In progress
07 November 2017 - 06 December 2017 Review proposal consultation

For further information on our processes and methods, please see our CHTE processes and methods manual